Diabetes Mellitus Clinical Trial
Official title:
The Glycemic Indices of Five Common Varieties of Dates in the Tested Among Healthy and Diabetic Subjects
The main objectives of this study is to measure the composition of five common types of
dates (Fara'd, Lulu, Abu ouma'n, Dabbas and Khalas) and to calculate their Glycemic Indices
(GI) of these dates tested in healthy and diabetic subjects. Thirteen healthy volunteers and
ten subjects with type 2 diabetes mellitus were enrolled in the study.
The dates' flesh composition analysis showed that the dates contain a high percentage of
carbohydrate (total sugars, 65-68%).
The measured mean glycemic indices of the dates among healthy individuals were 54.0, 53.5,
46.3, 49.1 and 55.1 for Fara'd, Lulu, Abu Ouma'n, Dabbas and Khalas, respectively.
Corresponding mean glycemic indices among individuals with type 2 diabetes were very similar
46.1, 43.8, 51.8, 50.2, and 53.0. Thus the tested five varieties of the dates are classified
as low glycemic index food items.
The United Arab Emirates (UAE) has transitioned rapidly over the last 40 years. This has
lead to a dramatic increase in the prevalence of obesity, metabolic syndrome, dyslipidaemia,
hypertension, prediabetes and diabetes. Daily consumption of dates is the norm.The main
objectives of this study is to measure the composition of five common types of dates
(Fara'd, Lulu, Abu ouma'n, Dabbas and Khalas) and to calculate their Glycemic Indices (GI)
of these dates tested equally in healthy and diabetic subjects. Thirteen healthy volunteers
and ten subjects with type 2 diabetes mellitus were enrolled in the study. The dates' flesh
composition analysis showed that the dates contain a high percentage of carbohydrate (total
sugars, 65-68%).
The measured mean glycemic indices of the dates among healthy individuals were 54.0, 53.5,
46.3, 49.1 and 55.1 for Fara'd, Lulu, Abu Ouma'n, Dabbas and Khalas, respectively.
Corresponding mean glycemic indices among individuals with type 2 diabetes were very similar
46.1, 43.8, 51.8, 50.2, and 53.0. Thus the tested five varieties of the dates are classified
as low glycemic index food items with potential health benefits for healthy and diabetic
individuals alike.
;
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |